ESR1 and breast carcinoma: To investigate the clinical utility of these signaling pathway models in terms of predicting therapy benefit, and of the ER pathway model in particular, we performed a multiple pathway model analysis on Affymetrix mRNA expression data from primary tumor tissue samples of a retrospective series of patients with ER positive breast cancer who did not receive adjuvant hormonal treatment and subsequently developed metastatic disease.